Randomized trial of lipid-based amphotericin B for invasive aspergillosis in neutropenic hosts is an important step forward.
Karp
J E
JE
Merz
W G
WG
D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D004337:Drug Carriers; D006801:Humans; D008081:Liposomes; D009503:Neutropenia / Q000150:complications*; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D016896:Treatment Outcome
D000935:Antifungal Agents; D004337:Drug Carriers; D008081:Liposomes; D000666:Amphotericin B